



Exvastat Ltd

Appointment of Dr Julian Gilbert as Non-Executive Director

Cambridge, UK [26th April 2021]: Exvastat Limited is pleased to announce the appointment of Dr Julian Gilbert to its Board as a Non-Executive Director.

Julian has more than 30 years of commercial and technical experience in the pharmaceutical industry gained at a number of companies including Chiroscience Plc, Mundipharma International Limited, BTG and GSK.

Most recently, Julian was co-founder and CEO of Acacia Pharma Group plc (Acacia), a leading hospital pharmaceuticals company, raising approximately £100 million in private and public funding and leading its flotation on Euronext in 2018. Acacia launched its lead product BARHEMSYS[®], for the management of PONV, in the US in 2020. Prior to this, he was co-founder and Commercial Director of Arakis Limited, a specialist pharmaceutical company repurposing known drugs, that was sold to Sosei in 2005 for £107 million, having licensed Seebri[®]/Ultibro[®] to Novartis. Julian has a degree in pharmacy and a PhD in pharmaceuticals, both from the University of Nottingham, and is a Non-Executive Director of Nuformix plc.

Dr Robert Tansley, Chairperson, Exvastat and Partner, Cambridge Innovation Capital, said "On behalf of Exvastat, I am delighted to welcome Julian to the board as the company prepares for its next stage of development. Julian's extensive commercial and development experience in the re-profiling space will enhance the company's capabilities as the company prepares for its Phase 3 program".

Dr Julian Gilbert, said "I am delighted to join Exvastat. There is a significant unmet medical need in Acute Respiratory Distress Syndrome. Impentri[®]'s unique mechanism of action has the potential to provide significant benefit in this patient group".

About Exvastat Ltd

Exvastat is a clinical stage company developing intravenous imatinib (Impentri©) as a first-in-class pharmacotherapy for COVID-19 pneumonia and all-cause ARDS to lower mortality and improve quality of life of patients. ARDS is a life-threatening respiratory condition with a high mortality and currently lacking any effective, licensed treatment.

For more information, please visit the Exvastat website at <http://www.exvastat.com/>.

About Cambridge Innovation Capital

Cambridge Innovation Capital (CIC) is a leading venture investor backing and building category-leading deep tech and life sciences companies. CIC currently manages more than £300 million and has invested in 30+ companies. CIC is a preferred investor for the University of Cambridge, Europe's top source of founders for venture-backed start-ups. Cambridge Innovation Capital Manager Limited (FRN:918898) is authorised and regulated by the Financial Conduct Authority. For more information please visit www.cic.vc or follow us on Twitter at [@CIC_vc](https://twitter.com/CIC_vc) and [Linkedin](https://www.linkedin.com/company/cic-vc).

For more information please contact:

Exvastat Ltd

David Cavalla, CEO

+44 (0)7746 770409

david.cavalla@exvastat.com

www.exvastat.com

Cambridge Innovation Capital

Robert Tansley, Partner

Michelle Lamprecht, Head of Marketing

+44 (0)7508 384298

enquiries@cic.vc

www.cic.vc